4.40 +0.43 (10.83%)
Pre-Market: 9:01AM EDT
|Bid||3.85 x 800|
|Ask||4.40 x 1000|
|Day's Range||3.90 - 3.97|
|52 Week Range||3.61 - 25.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.00|
Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied Microneedle (“ADAM™”) technology, today announced the release of three registration batches of M207, the Company’s lead development candidate. The registration batches will be used to support Zosano’s New Drug Application (NDA) filing with the U.S. Food and Drug Administration (FDA). Twelve months of room temperature stability for a product candidate are typically required in order for the FDA to assess manufacturability and stability of a drug product.
Every investor in Zosano Pharma Corporation (NASDAQ:ZSAN) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to seeRead More...
Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology called Adhesive Dermally-Applied Microarray (“ADAM™”), is scheduled to present an update on its ongoing Phase 3 long-term safety trial utilizing its proprietary ADAM technology for the delivery of zolmitriptan at the 5th Annual Transdermal & Intradermal Drug Delivery Systems Conference being held on September 6-7, 2018 in Philadelphia, PA. “Our ADAM technology continues to perform well in clinical studies, which supports the potential to develop ADAM with new drugs for additional indications. One of the major potential advantages of our ADAM technology is the ability to effectively deliver a drug through the skin, as some drugs have poor oral bioavailability and slow intestinal absorption," said Dr. Donald Kellerman, vice president of clinical development and medical affairs at Zosano.
FREMONT, Calif., Sept. 05, 2018-- Zosano Pharma Corporation, a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary ...
Completed enrollment for our M207-ADAM study with 344 subjects Presented additional analyses from the ZOTRIP pivotal study on pain relief and recurrence at the 2018 American Headache Society meeting Published ...
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Zosano Pharma Corp. (NASDAQ: ZSAN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 4:30 PM Eastern Time. ...
Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied Microarray (ADAM™) technology, today announced that it will host a conference call and webcast to be held on Thursday, August 9, 2018 at 4:30PM ET. The Company will announce its financial results for this period in a press release to be issued prior to the call. To access the live webcast, please visit the Investor Relations page of the Zosano Pharma website at http://ir.zosanopharma.com/events.cfm.
For today, WallStEquities.com assesses vTv Therapeutics Inc. (NASDAQ: VTVT), Voyager Therapeutics Inc. (NASDAQ: VYGR), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Zosano Pharma Corp. (NASDAQ: ZSAN). High Point, North Carolina headquartered vTv Therapeutics Inc.'s stock saw a decline of 3.70%, finishing last Friday's trading session at $1.30. The Company's shares are trading below their 50-day moving average by 19.58%.
Today, Zosano Pharma is trading at a stock price of $4.38, which represents ~5.92% growth from its closing price of $4.14 yesterday. $4.14 represented ~15% growth from the stock’s 52-week low of $3.61 on February 13. Zosano Pharma hit a 52-week high of $27.8 on July 18, 2017.
Peer-reviewed article published in Journal of Pharmaceutical Science evaluates skin tolerability and bioavailability of ADAM’ s intracutaneous zolmitriptan delivery. FREMONT, Calif., July 17, 2018-- Zosano ...
Stock Research Monitor: VYGR, VTVT, and ZSAN LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want a free Stock Review on ZIOP sign up now at www.wallstequities.com/registration . WallStEquities.com recalls ...
Yes, you're reading this right. BTIG analyst Robert Hazlett is expecting Zosano Pharma (NASDAQ:ZSAN) shares to reach $19.00 in the next 12 months, which implies an upside of 400% from current levels. In a very upbeat and promising report, Hazlett explains why he is initiating coverage on ZSAN with a Buy rating: "We believe M&A potential exists with Zosano [...] Since Zosano is effectively a one product company with a modest infrastructure, there is a reasonable chance that a larger industry suitor could emerge and take over the company’s operations. The analyst continued, "We assess the total value of M207 at $16.21 per ZSAN share, assuming Zosano continues to operate independently.
Zosano Pharma, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies that deliver rapid systemic absorption using a novel and proprietary technology called Adhesive Dermally-Applied Microarray (“ADAM™”) with the potential to transform patient lives and advance patient care, announced additional analyses from the Phase 2/3 clinical study on pain relief by time and recurrence of migraine in subjects with pain relief at two hours will be presented at the American Headache Society Meeting. A poster and oral presentation on receptor and binding kinetics will also be presented during the 60th Annual Scientific Meeting to be held on June 28 – July 1, 2018 in San Francisco, CA.
Under evaluation this morning are these four equities: VIVUS Inc. (NASDAQ: VVUS), Voyager Therapeutics Inc. (NASDAQ: VYGR), vTv Therapeutics Inc. (NASDAQ: VTVT), and Zosano Pharma Corp. (NASDAQ: ZSAN). Shares in Campbell, California headquartered VIVUS Inc. plummeted 14.00%, ending Tuesday's trading session at $0.79.